OTCM
SOAGY
Market cap15bUSD
Oct 08, Last price
56.03USD
1D
-3.74%
1Q
1.09%
Name
Sartorius AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sartorius AG, a German company established in 1870 and based in Göttingen, is a global supplier of innovative bioprocess solutions and laboratory products and services. The company's extensive portfolio supports life science research, biopharmaceutical manufacturing, quality control, and other applied industries worldwide. Its offerings encompass a wide array of sophisticated tools and consumables, including: Advanced Analytics: Biosensors, label-free detection, and SPR systems; live-cell analysis platforms, flow cytometry, and related reagents. Cell Culture and Fermentation: Various bioreactors (e.g., single-use, stainless steel, benchtop) along with specialized media (for antibodies, recombinant proteins, stem cells, viral vaccines) and other essential reagents like buffers and microcarriers. Filtration and Separation: A comprehensive range of membranes, filter papers, syringe filters, and diverse filtration and ultrafiltration devices for sterile processing, sample preparation, and clarification. Laboratory Essentials: Weighing and pipetting systems, centrifuges, industrial microbiology systems, and water purification units. Process Solutions: Fluid management, process chromatography, and advanced analytical technologies coupled with data analytics. Beyond products, Sartorius provides crucial support services such as bioprocess development and engineering, protein expression system services, media and process optimization, testing, instrument services, and validation assistance.
Related entities
Subsidiaries (8)
SARTORIUS INDIA PRIVATE LIMITED
Sartorius Lab Holding GmbH
Sartorius Lab Instruments GmbH & Co. KG
Sartorius Stedim FMT SAS
SARTORIUS STEDIM INDIA PRIVATE LIMITED
Sartorius Weighing Technology GmbH
Sartorius Stedim Biotech GmbH
Key people
Chairman of the Supervisory Board, Shareholder Representative · since 2021
Michael Grosse
Chairman of the Executive Board, Chief Executive Officer, Member of the Executive Board · since 2025
Rene Faber
Member of the Executive Board, Head - Bioprocess Solutions Division and Chief Executive Officer of Sartorius Biotech SA · since 2019
Chief Financial Officer, Member of the Executive Board · since 2024
Alexandra Gatzemeyer
Member of the Executive Board, Head - Lab Products & Services Division · since 2023
Daniela Favoccia
Independent Member of the Supervisory Board, Shareholder Representative · since 2021
Ilke Panzer
Independent Member of the Supervisory Board, Shareholder Representative · since 2017
Annette Becker
Member of the Supervisory Board · since 2021
Independent Member of the Supervisory Board · since 2020
Dietmar Mueller
Deputy Chairman of the Supervisory Board, Employee Representative · since 2026
Independent Member of the Supervisory Board, Shareholder Representative · since 2022
Hermann Ritzau
Member of the Supervisory Board, Employee Representative · since 2021
Klaus Truetzschler
Independent Member of the Supervisory Board, Shareholder Representative · since 2021
Sabrina Wirth
Member of the Supervisory Board, Employee Representative · since 2022
Legal address
Otto-Brenner-Straße 20
Göttingen, NI 37079
DE
Göttingen, NI 37079
DE
Headquarters
Weender Landstraße 94-108
Göttingen, NI 37075
DE
Göttingen, NI 37075
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||